Rws Share Discussion Threads

[phillis] 06/4/2018 10:49

12 April trading statement in 2017 and 2016

[phillis] 28/3/2018 13:38

Looking forward to a stonking Trading Update in early April!

[fbrj] 16/2/2018 08:32

Interesting development at the other Brode company - LTG. They announced this morning that Goldman Sachs have been appointed joint corporate broker. Has put 6% on the share price already (following 6% the day before!)

[redartbmud] 15/2/2018 09:35

Share price perking up now.
Volume isn't great, but Hey ho.... Onwards and upwards.

[redartbmud] 14/2/2018 12:59

jeffian

C's high PER was unwarranted on two counts. Bad management and the type of business. I sometimes wonder what the analysts use for brainpower.
Rws is a growing business, which gives them a chance to reduce the Per with good results.
Just MHO

Steptoe has a good point. There are synergies to be found in supplier sourcing and more efficient use of management and admin personnel.

[toffeeman] 14/2/2018 12:29

Steptoe - they don't make anything!

If anything they will be under pressure to lower prices

[steptoes yard] 14/2/2018 12:28

RWS will be a beneficiary of a Declining Cost Curve.

[orange1] 14/2/2018 12:11

Thanks from me too. Nice to receive reassurance after the recent rollercoaster dip.

[redartbmud] 14/2/2018 11:56

jeffian

With respect, C'r'apita is a bad example.
Their share service department reputation is appalling, and the level of consistent incompetence is very difficult to match elsewhere. I cannot tell you the number of spats that I have had with them, and the fact that people that I have spoken to have little or no knowledge of what they are supposed to be doing.
Are any other parts of the business any better?
Hmm....

[jeffian] 14/2/2018 11:53

Thanks, Linhur.

[linhur] 14/2/2018 11:41

Good positive vibe at AGM.
This year will be a year of consolidation with cost savings being made from integration of the acquisitions and reorganisation of Life Sciences.
RWS will be watching bottom line closely in 2018.
Moravia offers opportunities in China particularly with large global companies and translation of their strategies at local level.
2018 will mostly see organic growth with some small acquisitions provided they fit the criteria.These criteria were set out at 2015 with RWS 5 year view to 2020.
Life Sciences in No 2 slot in USA in the areas in which they operate. No 1 Company may be taken private as runner up to RWS in recent M&A activity with RWS moving very efficiently and effectively to secure targets.

[jeffian] 14/2/2018 10:17

Re: #737,
True, but that can't go on forever. I always take the line that at some point, when a period of above-average growth is passed, the PER will revert to market average (around 14-15). There's nothing wrong with buying high PER stocks as long as you understand you are paying today for tomorrow's growth and when that growth slows down you will be running to stand still. The best example was Capita which, on the back of 50%+ per annum revenue growth in the early years of 'outsourcing', was at one time valued at 150x earnings. Sure, earnings did grow but as the PER fell back to more normal level, the share price stagnated for years and then fell. Not saying this specific to RWS - still plenty of growth here IMHO - but just a comment to be wary of high PER's. They don't stay high forever!

[redartbmud] 14/2/2018 10:09

My spies at the AGM were happy with proceedings,
and with the progress, thus far, on the integration
of the new business.

[discodave4] 14/2/2018 09:49

Not when it's been trading with PE's in the 30's.

[jimbowen30] 14/2/2018 09:47

Numis are now forecasting eps of 18.1p and 19.4p for 2018/19. So a PE of 22 for 2019 isn't excessive for a growth company with such a good track record.

[mfhmfh] 13/2/2018 13:23

Post 730 seems to put everything into context IMHO

[mfhmfh] 13/2/2018 12:12

IC says buy

[fbrj] 13/2/2018 11:33

Numis 13 Feb - Add - Target Price 490p (same as before)

[martinthebrave] 13/2/2018 09:59

For what its worth:

Feb 2014 PE 23x EPS Growth 10.3%
Feb 2015 PE 20x EPS Growth 9.3%
Feb 2016 PE 20.3x EPS Growth 20.8%
Feb 2017 PE 27.4x EPS Growth 21.3%
Feb 2018 PE 22.6x EPS Growth 33%

EPS Growth is 12 month rolling from Stockopedia.

Looks attractive on that basis IMO.

[discodave4] 13/2/2018 09:13

Goes with saying with 85% rev $, but "Exposure to the US Dollar is more balanced as the Group has dollar debt and dollar revenues."They also have a very good Euro hedge in place.DD

[phillis] 13/2/2018 09:07

Big $ content in Group revenues (and a lot of $ interest)
RNS says notwithstanding a strong $ forecasts are being met